Protocol Ledger

Investor & Clinical Operations Playbook · Empirical Biostatistics Study

Quantitative Biotech Pipeline Auditing: Evaluating Enrollment Velocity, Site Concentration and Registry Provenance

Combining 793,923 disclosed hospital facility slots on clinicaltrials.gov (canonicalized across 49,607 campus merges into 22,436 physical sites) with 2,830 sponsor-linked fda.gov NDA and BLA approvals provides biotech investors and clinical operations teams a quantitative due diligence checklist for enrollment velocity, site congestion, and subsidiary M&A lineage.

Published: 2026-11-18 Publication ID: 47c4426df7e9d67d5bfe Primary Sources: clinicaltrials.gov & fda.gov

Moving Pipeline Diligence Beyond Mechanism-of-Action Slide Decks

During biotech crossover financings, licensing negotiations, and Phase III pivotal site selection, diligence teams devote exhaustive attention to preclinical pharmacology and Phase Ib waterfall plots while treating clinical execution timelines as fixed calendar assumptions. Yet our empirical audit of 54,890 Phase II and Phase III protocols proves that operational execution drives value destruction just as decisively as clinical biology: 1,629 trials collapsed purely from slow recruitment, and closed Oncology studies terminate nearly half the time (47.35%).

To replace qualitative CRO assurances with hard empirical baselines, Protocol Ledger links 784,367 deduplicated protocol-to-hospital execution arcs across 22,436 canonical medical centers and 4,879 sponsors. Below is a five-gate quantitative auditing framework built directly from reconciled federal records.

Gate 1 & Gate 2: Hospital Competing-Trial Congestion and Campus Entity Resolution

Emerging oncology and immunology biotechs frequently tout site lists anchored exclusively by marquee NCI-designated Comprehensive Cancer Centers. While academic hubs provide indispensable translational prestige, Table 1 reveals extraordinary concurrent competing-protocol loads at top U.S. academic campuses: MD Anderson Cancer Center runs 1,087 active Phase II/III protocols simultaneously (576 actively recruiting today), Washington University / Siteman Cancer Center runs 902, Memorial Sloan Kettering runs 832, Mayo Clinic Rochester runs 780, and California's flagship UCLA Jonsson (701), Stanford (644), and UCSF Helen Diller (641) campuses each manage over six hundred concurrent studies.

Without canonical entity resolution, this congestion is invisible in raw ClinicalTrials.gov downloads because hospital names appear under dozens of inconsistent strings (such as MDACC, M.D. Anderson (Site 0015), or IRB-prefixed clinic labels). Protocol Ledger executes 49,607 deterministic campus merges across 325,453 raw facility tuples while strictly preserving distinct geographic campuses (for example, keeping Mayo Clinic Rochester, Scottsdale/Phoenix, and Jacksonville separate).

Table 1. Top 10 U.S. Clinical Research Campuses Ranked by Concurrent Active Phase II and Phase III Protocol Load
Canonical Medical Center Campus City, State Total Trials Active Load Recruiting Now Completed Stopped Stop %
MD Anderson Cancer Center Houston, TX 1,694 1,087 576 256 313 18.48%
Washington University and Siteman Cancer Center Saint Louis, MO 1,592 902 437 417 243 15.26%
Memorial Sloan Kettering Cancer Center New York, NY 1,190 832 423 185 158 13.28%
Mayo Clinic Rochester Rochester, MN 1,349 780 380 355 188 13.94%
Ohio State University Comprehensive Cancer Center Columbus, OH 1,221 739 380 266 198 16.22%
Emory Winship Cancer Institute Atlanta, GA 1,258 719 371 315 195 15.50%
UCLA Health and Jonsson Comprehensive Cancer Center Los Angeles, CA 1,304 701 322 377 201 15.41%
Dana-Farber Cancer Institute Boston, MA 1,002 674 323 160 144 14.37%
Duke University Medical Center Durham, NC 1,172 664 342 311 182 15.53%
Northwestern Memorial and Lurie Cancer Center Chicago, IL 1,186 660 277 325 176 14.84%

Gate 3, Gate 4 & Gate 5: M&A Lineage, Accrual Velocity, and Drugs@FDA Conversion

Consolidating Acquired Biotech Subsidiaries Across 37 Parent Trees

Evaluating a large biopharma acquirer or licensing partner on raw LeadSponsorName strings misses thousands of acquired clinical assets that remain registered under legacy biotech subsidiary names years after deal close. Protocol Ledger consolidates 3,327 subsidiary protocols across 156 distinct corporate names into 37 M&A parent trees (such as Seagen, Arena, and Biohaven under Pfizer; Celgene, Mirati, Karuna, Turning Point, and RayzeBio under Bristol Myers Squibb; Alexion, Acerta, CinCor, and Fusion under AstraZeneca; Allergan, Pharmacyclics, and ImmunoGen under AbbVie; and Loxo, DICE, Morphic, and POINT Biopharma under Eli Lilly). Auditing post-acquisition strategic stop spikes (WS2) shows how acquirers prune overlapping pipeline assets within 12 to 24 months of closing.

Benchmarking Enrollment Velocity and FDA NDA/BLA Conversion

Before underwriting a sponsor's projected primary completion quarter, calculate implied enrollment velocity (target_patients / disclosed_sites / planned_months) against the therapeutic-area medians in our ledger and verify historical regulatory execution across 2,830 sponsor-linked original NDA and BLA approvals from Drugs@FDA.

Table 2. Five-Gate Quantitative Biotech Clinical Pipeline Due Diligence Matrix
Diligence Gate Primary Registry Metric Cohort Empirical Baseline Practitioner Red Flag & Audit Action
1. Site Congestion Concurrent active Phase II/III protocols per hospital 640 to 1,087 at top AMCs 100% academic-hub concentration without dedicated community network sites
2. Site Disclosure Named hospital slots vs anonymized CRO placeholders 83.66% named cohort-wide <50% disclosed physical sites prevents independent geographic accrual checks
3. Accrual Velocity Target N vs indication median enrollment & days 43 N / 1,269d (ONC); 113 N / 616d (END) Projected completion <50% of indication median duration without biomarker breadth
4. Status Hygiene Verified recruiting updates vs stale UNKNOWN lag 8,352 stale studies (15.22%) Unupdated record >12 months or multiple Primary Completion Date pushouts
5. M&A & FDA Lineage Subsidiary stop history & linked Drugs@FDA approvals 37 M&A trees / 2,830 NDAs/BLAs Unconsolidated subsidiary safety stops (WS4) or zero prior pivotal completions

Balancing Academic Prestige Against Dedicated Community Trial Networks

Sponsor execution profiles in Protocol Ledger show that biopharma teams achieving predictable completion medians in cardiometabolic, respiratory, immunology, and late-stage oncology programs pair flagship academic centers of excellence with dedicated multi-specialty community research networks. Community clinics typically carry far lower competing-protocol congestion per principal investigator, faster central IRB activation turnaround (often 3 to 5 weeks vs 4 to 7 months at academic medical centers), and broader geographic access to diverse patient populations across suburban and inland metro areas.

Methodology and Workbench Workflow

Practitioners can run side-by-side institutional and sponsor audits directly inside the Comparison Matrix (configured to compare up to four sponsors or medical centers simultaneously) and inspect regional hub patterns across Boston, New York, Houston, the San Francisco Bay Area, Los Angeles, San Diego, and the Midwest inside the 3D Site Capacity Map.